September, 2025
September 2025
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Hagop Kantarjian: Low-dose azacitidine plus venetoclax – in patients with AML unable to complete standard consolidation strategies
Apr 5, 2024, 08:22

Hagop Kantarjian: Low-dose azacitidine plus venetoclax – in patients with AML unable to complete standard consolidation strategies

Hagop Kantarjian, Professor and Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, shared a post on X:

“Low-dose azacitidine plus venetoclax maintains remissions with manageable side effects in patients with AML unable to complete standard consolidation strategies (2-year modified RFS and OS of 56% and 72%).”

Hagop Kantarjian: Low-dose azacitidine plus venetoclax - in patients with AML unable to complete standard consolidation strategies

Proceed to the article.
Source: Hagop Kantarjian/X